{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T15:30:35Z","timestamp":1794670235972,"version":"4.9.1"},"reference-count":135,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T00:00:00Z","timestamp":1779062400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T00:00:00Z","timestamp":1779062400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1007\/s40265-026-02331-z","type":"journal-article","created":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T16:52:36Z","timestamp":1779123156000},"page":"1045-1073","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Antibody\u2013Drug Conjugates in Non-small Cell Lung Cancer"],"prefix":"10.1007","volume":"86","author":[{"given":"Lodovica","family":"Zullo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Bortolot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca R.","family":"Ogliari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie P. L.","family":"Saw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robin","family":"van Geel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rob","family":"ter Heine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Sadowska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordi","family":"Remon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3521-2535","authenticated-orcid":false,"given":"Lizza","family":"Hendriks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,18]]},"reference":[{"key":"2331_CR1","doi-asserted-by":"publisher","DOI":"10.1016\/j.canep.2024.102693","volume":"93","author":"J Zhou","year":"2024","unstructured":"Zhou J, Xu Y, Liu J, Feng L, Yu J, Chen D. Global burden of lung cancer in 2022 and projections to 2050: incidence and mortality estimates from GLOBOCAN. Cancer Epidemiol. 2024;93:102693. https:\/\/doi.org\/10.1016\/j.canep.2024.102693.","journal-title":"Cancer Epidemiol"},{"key":"2331_CR2","doi-asserted-by":"publisher","first-page":"165","DOI":"10.3322\/caac.21705","volume":"72","author":"P Tarantino","year":"2022","unstructured":"Tarantino P, Carmagnani Pestana R, Corti C, et al. Antibody\u2013drug conjugates: smart chemotherapy delivery across tumor histologies. CA Cancer J Clin. 2022;72:165\u201382. https:\/\/doi.org\/10.3322\/caac.21705.","journal-title":"CA Cancer J Clin"},{"key":"2331_CR3","doi-asserted-by":"publisher","DOI":"10.3390\/molecules26102943","volume":"26","author":"S Baah","year":"2021","unstructured":"Baah S, Laws M, Rahman KM. Antibody\u2013drug conjugates\u2014a tutorial review. Molecules. 2021;26:2943. https:\/\/doi.org\/10.3390\/molecules26102943.","journal-title":"Molecules"},{"key":"2331_CR4","doi-asserted-by":"publisher","first-page":"1736","DOI":"10.1038\/bjc.2017.367","volume":"117","author":"AH Staudacher","year":"2017","unstructured":"Staudacher AH, Brown MP. Antibody drug conjugates and bystander killing: is antigen-dependent internalisation required? Br J Cancer. 2017;117:1736\u201342. https:\/\/doi.org\/10.1038\/bjc.2017.367.","journal-title":"Br J Cancer"},{"key":"2331_CR5","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1038\/s41571-021-00470-8","volume":"18","author":"JZ Drago","year":"2021","unstructured":"Drago JZ, Modi S, Chandarlapaty S. Unlocking the potential of antibody\u2013drug conjugates for cancer therapy. Nat Rev Clin Oncol. 2021;18:327\u201344. https:\/\/doi.org\/10.1038\/s41571-021-00470-8.","journal-title":"Nat Rev Clin Oncol"},{"key":"2331_CR6","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1208\/s12248-014-9710-8","volume":"17","author":"JR McCombs","year":"2015","unstructured":"McCombs JR, Owen SC. Antibody drug conjugates: design and selection of linker, payload and conjugation chemistry. AAPS J. 2015;17:339\u201351. https:\/\/doi.org\/10.1208\/s12248-014-9710-8.","journal-title":"AAPS J"},{"key":"2331_CR7","doi-asserted-by":"publisher","first-page":"6389","DOI":"10.1158\/1078-0432.CCR-11-1417","volume":"17","author":"BA Teicher","year":"2011","unstructured":"Teicher BA, Chari RVJ. Antibody conjugate therapeutics: challenges and potential. Clin Cancer Res. 2011;17:6389\u201397. https:\/\/doi.org\/10.1158\/1078-0432.CCR-11-1417.","journal-title":"Clin Cancer Res"},{"key":"2331_CR8","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-022-00947-7","volume":"7","author":"Z Fu","year":"2022","unstructured":"Fu Z, Li S, Han S, Shi C, Zhang Y. Antibody drug conjugate: the \u201cbiological missile\u201d for targeted cancer therapy. Sig Transduct Target Ther. 2022;7:93. https:\/\/doi.org\/10.1038\/s41392-022-00947-7.","journal-title":"Sig Transduct Target Ther"},{"key":"2331_CR9","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1093\/jnci\/djz035","volume":"111","author":"MJ Birrer","year":"2019","unstructured":"Birrer MJ, Moore KN, Betella I, Bates RC. Antibody-drug conjugate-based therapeutics: state of the science. J Natl Cancer Inst. 2019;111:538\u201349. https:\/\/doi.org\/10.1093\/jnci\/djz035.","journal-title":"J Natl Cancer Inst"},{"key":"2331_CR10","doi-asserted-by":"publisher","first-page":"3286","DOI":"10.21037\/tcr-2025-400","volume":"14","author":"H Aboaid","year":"2025","unstructured":"Aboaid H, Myat YM, Jones DT, Thein KZ. Trastuzumab deruxtecan: expanding the role of HER2-targeted therapy in solid tumors. Transl Cancer Res. 2025;14:3286\u201391. https:\/\/doi.org\/10.21037\/tcr-2025-400.","journal-title":"Transl Cancer Res"},{"key":"2331_CR11","doi-asserted-by":"publisher","first-page":"3577","DOI":"10.1007\/s11095-015-1729-8","volume":"32","author":"S Xu","year":"2015","unstructured":"Xu S. Internalization, trafficking, intracellular processing and actions of antibody-drug conjugates. Pharm Res. 2015;32:3577\u201383. https:\/\/doi.org\/10.1007\/s11095-015-1729-8.","journal-title":"Pharm Res"},{"key":"2331_CR12","doi-asserted-by":"publisher","DOI":"10.1208\/s12248-019-0387-x","volume":"22","author":"AP Singh","year":"2020","unstructured":"Singh AP, Guo L, Verma A, Wong GG-L, Thurber GM, Shah DK. Antibody coadministration as a strategy to overcome binding-site barrier for ADCs: a quantitative investigation. AAPS J. 2020;22:28. https:\/\/doi.org\/10.1208\/s12248-019-0387-x.","journal-title":"AAPS J"},{"key":"2331_CR13","doi-asserted-by":"publisher","first-page":"4145","DOI":"10.1158\/0008-5472.CAN-20-3822","volume":"81","author":"BM Bordeau","year":"2021","unstructured":"Bordeau BM, Yang Y, Balthasar JP. Transient competitive inhibition bypasses the binding site barrier to improve tumor penetration of Trastuzumab and enhance T-DM1 efficacy. Cancer Res. 2021;81:4145\u201354. https:\/\/doi.org\/10.1158\/0008-5472.CAN-20-3822.","journal-title":"Cancer Res"},{"key":"2331_CR14","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.01296","volume":"10","author":"KO Saunders","year":"2019","unstructured":"Saunders KO. Conceptual approaches to modulating antibody effector functions and circulation half-life. Front Immunol. 2019;10:1296. https:\/\/doi.org\/10.3389\/fimmu.2019.01296.","journal-title":"Front Immunol"},{"key":"2331_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.drudis.2024.104241","volume":"29","author":"M Grairi","year":"2024","unstructured":"Grairi M, Le Borgne M. Antibody-drug conjugates: prospects for the next generation. Drug Discov Today. 2024;29:104241. https:\/\/doi.org\/10.1016\/j.drudis.2024.104241.","journal-title":"Drug Discov Today"},{"key":"2331_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2023.113379","volume":"195","author":"C Bosi","year":"2023","unstructured":"Bosi C, Bartha \u00c1, Galbardi B, et al. Pan-cancer analysis of antibody-drug conjugate targets and putative predictors of treatment response. Eur J Cancer. 2023;195:113379. https:\/\/doi.org\/10.1016\/j.ejca.2023.113379.","journal-title":"Eur J Cancer"},{"key":"2331_CR17","doi-asserted-by":"publisher","first-page":"3000","DOI":"10.1200\/JCO.24.00720","volume":"42","author":"DR Camidge","year":"2024","unstructured":"Camidge DR, Bar J, Horinouchi H, et al. Telisotuzumab vedotin monotherapy in patients with previously treated c-Met protein\u2013overexpressing advanced nonsquamous EGFR-wildtype non-small cell lung cancer in the phase II LUMINOSITY trial. J Clin Oncol. 2024;42:3000\u201311. https:\/\/doi.org\/10.1200\/JCO.24.00720.","journal-title":"J Clin Oncol"},{"key":"2331_CR18","doi-asserted-by":"publisher","first-page":"4678","DOI":"10.1200\/JCO.23.00059","volume":"41","author":"T Shimizu","year":"2023","unstructured":"Shimizu T, Sands J, Yoh K, et al. First-in-human, phase I dose-escalation and dose-expansion study of trophoblast cell-surface antigen 2-directed antibody-drug conjugate datopotamab deruxtecan in non-small-cell lung cancer: TROPION-PanTumor01. J Clin Oncol. 2023;41:4678\u201387. https:\/\/doi.org\/10.1200\/JCO.23.00059.","journal-title":"J Clin Oncol"},{"key":"2331_CR19","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1016\/j.annonc.2022.12.009","volume":"34","author":"LE Hendriks","year":"2023","unstructured":"Hendriks LE, Kerr KM, Menis J, et al. Oncogene-addicted metastatic non-small-cell lung cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Ann Oncol. 2023;34:339\u201357. https:\/\/doi.org\/10.1016\/j.annonc.2022.12.009.","journal-title":"Ann Oncol"},{"key":"2331_CR20","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1016\/j.annonc.2022.12.013","volume":"34","author":"LE Hendriks","year":"2023","unstructured":"Hendriks LE, Kerr KM, Menis J, et al. Non-oncogene-addicted metastatic non-small-cell lung cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Ann Oncol. 2023;34:358\u201376. https:\/\/doi.org\/10.1016\/j.annonc.2022.12.013.","journal-title":"Ann Oncol"},{"key":"2331_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2025.108797","volume":"209","author":"I Gomez-Randulfe","year":"2025","unstructured":"Gomez-Randulfe I, Monaca F, Cantale O, et al. Real-world outcomes of second-line carboplatin plus pemetrexed after first-line osimertinib in EGFR-mutant advanced NSCLC: an international multicentre cohort study. Lung Cancer. 2025;209:108797. https:\/\/doi.org\/10.1016\/j.lungcan.2025.108797.","journal-title":"Lung Cancer"},{"key":"2331_CR22","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1056\/NEJMoa1713137","volume":"378","author":"J-C Soria","year":"2018","unstructured":"Soria J-C, Ohe Y, Vansteenkiste J, et al. Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer. N Engl J Med. 2018;378:113\u201325. https:\/\/doi.org\/10.1056\/NEJMoa1713137.","journal-title":"N Engl J Med"},{"key":"2331_CR23","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1056\/NEJMoa1913662","volume":"382","author":"SS Ramalingam","year":"2020","unstructured":"Ramalingam SS, Vansteenkiste J, Planchard D, et al. Overall survival with Osimertinib in untreated, EGFR-mutated advanced NSCLC. N Engl J Med. 2020;382:41\u201350. https:\/\/doi.org\/10.1056\/NEJMoa1913662.","journal-title":"N Engl J Med"},{"key":"2331_CR24","doi-asserted-by":"publisher","first-page":"1935","DOI":"10.1056\/NEJMoa2306434","volume":"389","author":"D Planchard","year":"2023","unstructured":"Planchard D, J\u00e4nne PA, Cheng Y, et al. Osimertinib with or without chemotherapy in EGFR-mutated advanced NSCLC. N Engl J Med. 2023;389:1935\u201348. https:\/\/doi.org\/10.1056\/NEJMoa2306434.","journal-title":"N Engl J Med"},{"key":"2331_CR25","doi-asserted-by":"publisher","first-page":"1681","DOI":"10.1056\/NEJMoa2503001","volume":"393","author":"JC-H Yang","year":"2025","unstructured":"Yang JC-H, Lu S, Hayashi H, et al. Overall survival with amivantamab\u2013lazertinib in EGFR-mutated advanced NSCLC. N Engl J Med. 2025;393:1681\u201393. https:\/\/doi.org\/10.1056\/NEJMoa2503001.","journal-title":"N Engl J Med"},{"key":"2331_CR26","doi-asserted-by":"publisher","first-page":"8506","DOI":"10.1200\/JCO.2025.43.16_suppl.8506","volume":"43","author":"TSK Mok","year":"2025","unstructured":"Mok TSK, Yu HA, Lim SM, et al. Patritumab deruxtecan (HER3-DXd) in resistant EGFR-mutated (EGFRm) advanced non-small cell lung cancer (NSCLC) after a third-generation EGFR TKI: the phase 3 HERTHENA-Lung02 study. J Clin Oncol. 2025;43:8506\u20138506. https:\/\/doi.org\/10.1200\/JCO.2025.43.16_suppl.8506.","journal-title":"J Clin Oncol"},{"key":"2331_CR27","doi-asserted-by":"publisher","first-page":"5363","DOI":"10.1200\/JCO.23.01476","volume":"41","author":"HA Yu","year":"2023","unstructured":"Yu HA, Goto Y, Hayashi H, et al. HERTHENA-Lung01, a phase II trial of Patritumab Deruxtecan (HER3-DXd) in epidermal growth factor receptor\u2013mutated non\u2013small-cell lung cancer after epidermal growth factor receptor tyrosine kinase inhibitor therapy and platinum-based chemotherapy. J Clin Oncol. 2023;41:5363\u201375. https:\/\/doi.org\/10.1200\/JCO.23.01476.","journal-title":"J Clin Oncol"},{"key":"2331_CR28","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1016\/j.annonc.2024.02.003","volume":"35","author":"HA Yu","year":"2024","unstructured":"Yu HA, Baik C, Kim D-W, et al. Translational insights and overall survival in the U31402-A-U102 study of patritumab deruxtecan (HER3-DXd) in EGFR-mutated NSCLC. Ann Oncol. 2024;35:437\u201347. https:\/\/doi.org\/10.1016\/j.annonc.2024.02.003.","journal-title":"Ann Oncol"},{"key":"2331_CR29","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1200\/JCO-24-01544","volume":"43","author":"M-J Ahn","year":"2025","unstructured":"Ahn M-J, Tanaka K, Paz-Ares L, et al. Datopotamab deruxtecan versus docetaxel for previously treated advanced or metastatic non\u2013small cell lung cancer: the randomized, open-label phase III TROPION-Lung01 study. J Clin Oncol. 2025;43:260\u201372. https:\/\/doi.org\/10.1200\/JCO-24-01544.","journal-title":"J Clin Oncol"},{"key":"2331_CR30","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.1200\/JCO-24-01349","volume":"43","author":"J Sands","year":"2025","unstructured":"Sands J, Ahn M-J, Lisberg A, et al. Datopotamab deruxtecan in advanced or metastatic non\u2013small cell lung cancer with actionable genomic alterations: results from the phase II TROPION-Lung05 study. J Clin Oncol. 2025;43:1254\u201365. https:\/\/doi.org\/10.1200\/JCO-24-01349.","journal-title":"J Clin Oncol"},{"key":"2331_CR31","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2026.02.014","author":"JW Riess","year":"2026","unstructured":"Riess JW, Yu HA, Le X, et al. Osimertinib plus datopotamab deruxtecan in patients with EGFR-mutated advanced NSCLC post-progression on first-line osimertinib: ORCHARD. Ann Oncol. 2026. https:\/\/doi.org\/10.1016\/j.annonc.2026.02.014.","journal-title":"Ann Oncol"},{"key":"2331_CR32","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2025-085680","volume":"389","author":"W Fang","year":"2025","unstructured":"Fang W, Li X, Wang Q, et al. Sacituzumab tirumotecan versus docetaxel for previously treated EGFR-mutated advanced non-small cell lung cancer: multicentre, open label, randomised controlled trial. BMJ. 2025;389:e085680. https:\/\/doi.org\/10.1136\/bmj-2025-085680.","journal-title":"BMJ"},{"key":"2331_CR33","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa251207","author":"W Fang","year":"2025","unstructured":"Fang W, Wu L, Meng X, et al. Sacituzumab tirumotecan in EGFR-TKI-resistant, EGFR-mutated advanced NSCLC. N Engl J Med. 2025. https:\/\/doi.org\/10.1056\/NEJMoa251207. (published online Oct 19).","journal-title":"N Engl J Med"},{"key":"2331_CR34","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1158\/2159-8290.CD-21-0715","volume":"12","author":"PA J\u00e4nne","year":"2022","unstructured":"J\u00e4nne PA, Baik C, Su W-C, et al. Efficacy and safety of patritumab deruxtecan (HER3-DXd) in EGFR inhibitor-resistant, EGFR-mutated non-small cell lung cancer. Cancer Discov. 2022;12:74\u201389. https:\/\/doi.org\/10.1158\/2159-8290.CD-21-0715.","journal-title":"Cancer Discov"},{"key":"2331_CR35","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1016\/j.annonc.2025.01.001","volume":"36","author":"H Horinouchi","year":"2025","unstructured":"Horinouchi H, Cho BC, Camidge DR, et al. Results from a phase Ib study of telisotuzumab vedotin in combination with Osimertinib in patients with c-Met protein-overexpressing, EGFR-mutated locally advanced\/metastatic non-small-cell lung cancer (NSCLC) after progression on prior osimertinib. Ann Oncol. 2025;36:583\u201391. https:\/\/doi.org\/10.1016\/j.annonc.2025.01.001.","journal-title":"Ann Oncol"},{"key":"2331_CR36","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2025.12.080","author":"D Planchard","year":"2025","unstructured":"Planchard D, Kim HR, Suksombooncharoen T, et al. Trastuzumab deruxtecan in patients with HER2-overexpressing non-small cell lung cancer: results from part 1 of the open-label, multicenter, phase 1b DESTINY-Lung03 trial. J Thorac Oncol. 2025. https:\/\/doi.org\/10.1016\/j.jtho.2025.12.080.","journal-title":"J Thorac Oncol"},{"key":"2331_CR37","doi-asserted-by":"publisher","first-page":"3000","DOI":"10.1200\/JCO.2025.43.16_suppl.3000","volume":"43","author":"A Lisberg","year":"2025","unstructured":"Lisberg A, Lu S, Hamilton EP, et al. DB-1310, a HER3-targeted ADC, in pts with advanced solid tumors: preliminary results from the phase 1\/2a trial. J Clin Oncol. 2025;43:3000\u20133000. https:\/\/doi.org\/10.1200\/JCO.2025.43.16_suppl.3000.","journal-title":"J Clin Oncol"},{"key":"2331_CR38","doi-asserted-by":"publisher","unstructured":"Hong SD, Wang YS, Zhao HY, Zhao YY, Wang QM, Ma YX, et al Izalontamab brengitecan (Iza-bren; BL-B01D1), a first-in-class EGFR-HER3 bispecific antibody\u2013drug conjugate, for patients with EGFR-mutated NSCLC: pooled analysis of phase I and phase II trials. Ann Oncol. 2026;S0923-7534(26)00018-9. https:\/\/doi.org\/10.1016\/j.annonc.2026.01.009.","DOI":"10.1016\/j.annonc.2026.01.009"},{"key":"2331_CR39","unstructured":"Zhou, WCLC 2025 https:\/\/ascopost.com\/news\/september-2025\/izalontamab-brengitecan-plus-osimertinib-shows-activity-in-first-line-egfr-mutant-nsclc\/"},{"key":"2331_CR40","doi-asserted-by":"publisher","first-page":"8512","DOI":"10.1200\/JCO.2025.43.16_suppl.8512","volume":"43","author":"DR Camidge","year":"2025","unstructured":"Camidge DR, Raimbourg J, Lee Y-G, et al. Telisotuzumab adizutecan (ABBV-400; Temab-A), a c-Met protein\u2013targeting antibody-drug conjugate (ADC), in patients (pts) with advanced EGFR-mutated (MT) non-squamous (NSQ) non-small cell lung cancer (NSCLC): results from a phase 1 study. J Clin Oncol. 2025;43:8512\u20138512. https:\/\/doi.org\/10.1200\/JCO.2025.43.16_suppl.8512.","journal-title":"J Clin Oncol"},{"key":"2331_CR41","doi-asserted-by":"publisher","DOI":"10.1038\/srep33658","volume":"6","author":"P Zeng","year":"2016","unstructured":"Zeng P, Chen M-B, Zhou L-N, Tang M, Liu C-Y, Lu P-H. Impact of TROP2 expression on prognosis in solid tumors: a systematic review and meta-analysis. Sci Rep. 2016;6:33658. https:\/\/doi.org\/10.1038\/srep33658.","journal-title":"Sci Rep"},{"key":"2331_CR42","doi-asserted-by":"publisher","first-page":"2329","DOI":"10.1158\/1535-7163.MCT-21-0206","volume":"20","author":"D Okajima","year":"2021","unstructured":"Okajima D, Yasuda S, Maejima T, et al. Datopotamab deruxtecan, a novel TROP2-directed antibody-drug conjugate, demonstrates potent antitumor activity by efficient drug delivery to tumor cells. Mol Cancer Ther. 2021;20:2329\u201340. https:\/\/doi.org\/10.1158\/1535-7163.MCT-21-0206.","journal-title":"Mol Cancer Ther"},{"key":"2331_CR43","doi-asserted-by":"publisher","first-page":"1669","DOI":"10.1016\/j.jtho.2025.06.002","volume":"20","author":"M-J Ahn","year":"2025","unstructured":"Ahn M-J, Lisberg A, Goto Y, et al. A pooled analysis of datopotamab deruxtecan in patients with EGFR-mutated NSCLC. J Thorac Oncol. 2025;20:1669\u201382. https:\/\/doi.org\/10.1016\/j.jtho.2025.06.002.","journal-title":"J Thorac Oncol"},{"key":"2331_CR44","doi-asserted-by":"publisher","first-page":"8501","DOI":"10.1200\/JCO.2024.42.16_suppl.8501","volume":"42","author":"D Planchard","year":"2024","unstructured":"Planchard D, Cozic N, Wislez M, et al. ICARUS-LUNG01: a phase 2 study of datopotomab deruxtecan (Dato-DXd) in patients with previously treated advanced non-small cell lung cancer (NSCLC), with sequential tissue biopsies and biomarkers analysis to predict treatment outcome. J Clin Oncol. 2024;42:8501\u20138501. https:\/\/doi.org\/10.1200\/JCO.2024.42.16_suppl.8501.","journal-title":"J Clin Oncol"},{"key":"2331_CR45","doi-asserted-by":"publisher","DOI":"10.1136\/esmoopen-2016-000081","volume":"1","author":"J Remon","year":"2016","unstructured":"Remon J, Besse B. Unravelling signal escape through maintained EGFR activation in advanced non-small cell lung cancer (NSCLC): new treatment options. ESMO Open. 2016;1:e000081. https:\/\/doi.org\/10.1136\/esmoopen-2016-000081.","journal-title":"ESMO Open"},{"key":"2331_CR46","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1111\/1759-7714.14832","volume":"14","author":"L Hao","year":"2023","unstructured":"Hao L, Chen H, Wang L, et al. Transformation or tumor heterogeneity: mutations in EGFR, SOX2, TP53, and RB1 persist in the histological rapid conversion from lung adenocarcinoma to small-cell lung cancer. Thorac Cancer. 2023;14:1036\u201341. https:\/\/doi.org\/10.1111\/1759-7714.14832.","journal-title":"Thorac Cancer"},{"issue":"10","key":"2331_CR47","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2025.105807","volume":"10","author":"N Peled","year":"2025","unstructured":"Peled N, Tufman A, Sequist LV, et al. COMPEL: osimertinib plus platinum-based chemotherapy in patients with EGFR-mutated advanced NSCLC and progression on first-line osimertinib. ESMO Open. 2025;10(10):105807. https:\/\/doi.org\/10.1016\/j.esmoop.2025.105807.","journal-title":"ESMO Open"},{"key":"2331_CR48","doi-asserted-by":"publisher","first-page":"8501","DOI":"10.1200\/JCO.2025.43.16_suppl.8501","volume":"43","author":"BP Levy","year":"2025","unstructured":"Levy BP, Paz-Ares LG, Lin C-C, et al. TROPION-Lung02: Datopotamab deruxtecan (Dato-DXd) plus pembrolizumab (pembro) with or without platinum chemotherapy (Pt-CT) as first-line (1L) therapy for advanced non-small cell lung cancer (aNSCLC). J Clin Oncol. 2025;43:8501\u20138501. https:\/\/doi.org\/10.1200\/JCO.2025.43.16_suppl.8501.","journal-title":"J Clin Oncol"},{"key":"2331_CR49","doi-asserted-by":"publisher","unstructured":"Hong S, Wang Q, Cheng Y, et al. First-line sacituzumab tirumotecan with tagitanlimab in advanced non-small-cell lung cancer: a phase 2 trial. Nat Med. 2024;31:3654\u201361. https:\/\/doi.org\/10.1038\/s41591-025-03883-5.","DOI":"10.1038\/s41591-025-03883-5"},{"key":"2331_CR50","doi-asserted-by":"publisher","first-page":"1976","DOI":"10.1038\/s41591-025-03638-2","volume":"31","author":"S Zhao","year":"2025","unstructured":"Zhao S, Cheng Y, Wang Q, et al. Sacituzumab tirumotecan in advanced non-small-cell lung cancer with or without EGFR mutations: phase 1\/2 and phase 2 trials. Nat Med. 2025;31:1976\u201386. https:\/\/doi.org\/10.1038\/s41591-025-03638-2.","journal-title":"Nat Med"},{"key":"2331_CR51","doi-asserted-by":"publisher","first-page":"7151","DOI":"10.1158\/1078-0432.CCR-19-1745","volume":"25","author":"Y Hashimoto","year":"2019","unstructured":"Hashimoto Y, Koyama K, Kamai Y, et al. A novel HER3-targeting antibody-drug conjugate, U3-1402, exhibits potent therapeutic efficacy through the delivery of cytotoxic payload by efficient internalization. Clin Cancer Res. 2019;25:7151\u201361. https:\/\/doi.org\/10.1158\/1078-0432.CCR-19-1745.","journal-title":"Clin Cancer Res"},{"key":"2331_CR52","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1158\/0008-5472.CAN-21-2426","volume":"82","author":"HM Haikala","year":"2022","unstructured":"Haikala HM, Lopez T, K\u00f6hler J, et al. EGFR inhibition enhances the cellular uptake and antitumor-activity of the HER3 antibody-drug conjugate HER3-DXd. Cancer Res. 2022;82:130\u201341. https:\/\/doi.org\/10.1158\/0008-5472.CAN-21-2426.","journal-title":"Cancer Res"},{"key":"2331_CR53","unstructured":"WCLC 2025. https:\/\/cattendee.abstractsonline.com\/meeting\/21151\/Session\/208. Accessed 17 Nov 2025."},{"key":"2331_CR54","doi-asserted-by":"publisher","first-page":"2532","DOI":"10.1200\/JCO.2018.77.9777","volume":"36","author":"BT Li","year":"2018","unstructured":"Li BT, Shen R, Buonocore D, et al. Ado-Trastuzumab Emtansine for patients with HER2 -mutant lung cancers: results from a phase II basket trial. J Clin Oncol. 2018;36:2532\u20137. https:\/\/doi.org\/10.1200\/JCO.2018.77.9777.","journal-title":"J Clin Oncol"},{"key":"2331_CR55","unstructured":"National Comprehensive Cancer Network (NCCN). NCCN clinical practice guidelines in oncology."},{"key":"2331_CR56","doi-asserted-by":"publisher","first-page":"4852","DOI":"10.1200\/JCO.23.01361","volume":"41","author":"K Goto","year":"2023","unstructured":"Goto K, Goto Y, Kubo T, et al. Trastuzumab Deruxtecan in patients with HER2 -mutant metastatic non\u2013small-cell lung cancer: primary results from the randomized, phase II DESTINY-Lung02 trial. J Clin Oncol. 2023;41:4852\u201363. https:\/\/doi.org\/10.1200\/JCO.23.01361.","journal-title":"J Clin Oncol"},{"key":"2331_CR57","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1016\/S1470-2045(25)00012-9","volume":"26","author":"Z Li","year":"2025","unstructured":"Li Z, Wang Y, Sun Y, et al. Trastuzumab rezetecan, a HER2-directed antibody\u2013drug conjugate, in patients with advanced HER2-mutant non-small-cell lung cancer (HORIZON-Lung): phase 2 results from a multicentre, single-arm study. Lancet Oncol. 2025;26:437\u201346. https:\/\/doi.org\/10.1016\/S1470-2045(25)00012-9.","journal-title":"Lancet Oncol"},{"key":"2331_CR58","doi-asserted-by":"publisher","first-page":"S1820","DOI":"10.1016\/j.annonc.2025.10.997","volume":"36","author":"L Zhang","year":"2025","unstructured":"Zhang L, Fan Y, Zhao Y, et al. 160MO BL-M07D1, a novel anti-HER2 antibody-drug conjugate (ADC), in subjects with metastatic HER2-mutant non-small cell lung cancer (NSCLC). Ann Oncol. 2025;36:S1820\u20131. https:\/\/doi.org\/10.1016\/j.annonc.2025.10.997.","journal-title":"Ann Oncol"},{"key":"2331_CR59","doi-asserted-by":"publisher","first-page":"2816","DOI":"10.1200\/JCO-24-02744","volume":"43","author":"CE Steuer","year":"2025","unstructured":"Steuer CE, Hayashi H, Su W-C, et al. Patritumab deruxtecan (HER3-DXd; MK-1022) in non-small cell lung cancer after platinum-based chemotherapy and immunotherapy. J Clin Oncol. 2025;43:2816\u201326. https:\/\/doi.org\/10.1200\/JCO-24-02744.","journal-title":"J Clin Oncol"},{"key":"2331_CR60","volume":"0","author":"H Zhou","year":"2026","unstructured":"Zhou H, Zhao H, Hou X, et al. Izalontamab brengitecan in locally advanced or metastatic non\u2013small cell lung cancer with actionable genomic alterations outside of classical EGFR mutations: a phase Ib study. J Clin Oncol. 2026;0:JCO-25-01929.","journal-title":"J Clin Oncol"},{"key":"2331_CR61","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyaf251","volume":"30","author":"S Alhushki","year":"2025","unstructured":"Alhushki S, Deshmukh S, Levy B, Desai A. A tale of two TROP-2 antibody-drug conjugates: a comparative saga of datopotamab deruxtecan and sacituzumab govitecan. Oncologist. 2025;30:oyaf251. https:\/\/doi.org\/10.1093\/oncolo\/oyaf251.","journal-title":"Oncologist"},{"key":"2331_CR62","doi-asserted-by":"publisher","first-page":"2860","DOI":"10.1200\/JCO.24.00733","volume":"42","author":"LG Paz-Ares","year":"2024","unstructured":"Paz-Ares LG, Juan-Vidal O, Mountzios GS, et al. Sacituzumab Govitecan versus docetaxel for previously treated advanced or metastatic non\u2013small cell lung cancer: the randomized, open-label phase III EVOKE-01 study. J Clin Oncol. 2024;42:2860\u201372. https:\/\/doi.org\/10.1200\/JCO.24.00733.","journal-title":"J Clin Oncol"},{"key":"2331_CR63","doi-asserted-by":"publisher","first-page":"S25","DOI":"10.1016\/j.jtho.2024.09.050","volume":"19","author":"B Besse","year":"2024","unstructured":"Besse B, Lo Russo G, Lena H, et al. OA08.05 tusamitamab ravtansine vs docetaxel in previously treated advanced nonsquamous NSCLC: results from phase 3 CARMEN-LC03 Trial. J Thorac Oncol. 2024;19:S25\u20136. https:\/\/doi.org\/10.1016\/j.jtho.2024.09.050.","journal-title":"J Thorac Oncol"},{"key":"2331_CR64","doi-asserted-by":"publisher","first-page":"8585","DOI":"10.1200\/JCO.2024.42.16_suppl.8585","volume":"42","author":"K Muro","year":"2024","unstructured":"Muro K, Feinstein T, Baranda JC, et al. Enfortumab vedotin (EV) in non-squamous and squamous non\u2013small cell lung cancer (NSCLC) cohorts of EV-202. J Clin Oncol. 2024;42:8585\u20138585. https:\/\/doi.org\/10.1200\/JCO.2024.42.16_suppl.8585.","journal-title":"J Clin Oncol"},{"key":"2331_CR65","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1158\/1078-0432.CCR-24-1478","volume":"31","author":"SM Lee","year":"2025","unstructured":"Lee SM, Hamid O, Jotte R, et al. Phase II open-label trial of brentuximab vedotin with pembrolizumab in PD-1-pretreated metastatic non-small cell lung cancer and metastatic cutaneous melanoma. Clin Cancer Res. 2025;31:848\u201359. https:\/\/doi.org\/10.1158\/1078-0432.CCR-24-1478.","journal-title":"Clin Cancer Res"},{"key":"2331_CR66","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtocrr.2026.100988","author":"N Girard","year":"2026","unstructured":"Girard N, Goldman J, Lu S, et al. Telisotuzumab vedotin monotherapy in patients with previously treated c-Met protein overexpressing, non-squamous, EGFR-wildtype advanced NSCLC: updated analysis of the LUMINOSITY trial. JTO Clin Res Rep. 2026. https:\/\/doi.org\/10.1016\/j.jtocrr.2026.100988.","journal-title":"JTO Clin Res Rep"},{"key":"2331_CR67","doi-asserted-by":"publisher","first-page":"S54","DOI":"10.1016\/j.jtho.2023.09.041","volume":"18","author":"BC Cho","year":"2023","unstructured":"Cho BC, Dols MC, Reyes Cabanillas R, et al. OA05.04 sacituzumab govitecan + pembrolizumab in 1L metastatic non-small cell lung cancer: preliminary results of the EVOKE-02 Study. J Thorac Oncol. 2023;18:S54. https:\/\/doi.org\/10.1016\/j.jtho.2023.09.041.","journal-title":"J Thorac Oncol"},{"key":"2331_CR68","doi-asserted-by":"publisher","first-page":"2788","DOI":"10.1038\/s41591-025-03746-z","volume":"31","author":"T Cascone","year":"2025","unstructured":"Cascone T, Bonanno L, Guisier F, et al. Perioperative durvalumab plus chemotherapy plus new agents for resectable non-small-cell lung cancer: the platform phase 2 NeoCOAST-2 trial. Nat Med. 2025;31:2788\u201396. https:\/\/doi.org\/10.1038\/s41591-025-03746-z.","journal-title":"Nat Med"},{"key":"2331_CR69","doi-asserted-by":"publisher","first-page":"1672","DOI":"10.1056\/NEJMoa2304875","volume":"389","author":"JV Heymach","year":"2023","unstructured":"Heymach JV, Harpole D, Mitsudomi T, et al. Perioperative durvalumab for resectable non-small-cell lung cancer. N Engl J Med. 2023;389:1672\u201384. https:\/\/doi.org\/10.1056\/NEJMoa2304875.","journal-title":"N Engl J Med"},{"key":"2331_CR70","doi-asserted-by":"publisher","first-page":"1973","DOI":"10.1056\/NEJMoa2202170","volume":"386","author":"PM Forde","year":"2022","unstructured":"Forde PM, Spicer J, Lu S, et al. Neoadjuvant nivolumab plus chemotherapy in resectable lung cancer. N Engl J Med. 2022;386:1973\u201385. https:\/\/doi.org\/10.1056\/NEJMoa2202170.","journal-title":"N Engl J Med"},{"key":"2331_CR71","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1056\/NEJMoa2302983","volume":"389","author":"H Wakelee","year":"2023","unstructured":"Wakelee H, Liberman M, Kato T, et al. Perioperative Pembrolizumab for early-stage non-small-cell lung cancer. N Engl J Med. 2023;389:491\u2013503. https:\/\/doi.org\/10.1056\/NEJMoa2302983.","journal-title":"N Engl J Med"},{"key":"2331_CR72","doi-asserted-by":"publisher","first-page":"1756","DOI":"10.1056\/NEJMoa2311926","volume":"390","author":"T Cascone","year":"2024","unstructured":"Cascone T, Awad MM, Spicer JD, et al. Perioperative nivolumab in resectable lung cancer. N Engl J Med. 2024;390:1756\u201369. https:\/\/doi.org\/10.1056\/NEJMoa2311926.","journal-title":"N Engl J Med"},{"key":"2331_CR73","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1001\/jama.2023.24735","volume":"331","author":"S Lu","year":"2024","unstructured":"Lu S, Zhang W, Wu L, et al. Perioperative toripalimab plus chemotherapy for patients with resectable non-small cell lung cancer: the Neotorch randomized clinical trial. JAMA. 2024;331:201\u201311. https:\/\/doi.org\/10.1001\/jama.2023.24735.","journal-title":"JAMA"},{"key":"2331_CR74","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/S2213-2600(24)00269-8","volume":"13","author":"D Yue","year":"2025","unstructured":"Yue D, Wang W, Liu H, et al. Perioperative Tislelizumab plus neoadjuvant chemotherapy for patients with resectable non-small-cell lung cancer (RATIONALE-315): an interim analysis of a randomised clinical trial. Lancet Respir Med. 2025;13:119\u201329. https:\/\/doi.org\/10.1016\/S2213-2600(24)00269-8.","journal-title":"Lancet Respir Med"},{"key":"2331_CR75","doi-asserted-by":"publisher","first-page":"TPS8120","DOI":"10.1080\/14796694.2025.2591213","volume":"43","author":"FC Althoff","year":"2025","unstructured":"Althoff FC, Acker F, Koschade S, et al. Neotrace: a multicenter phase II study of neoadjuvant sacituzumab govitecan plus zimberelimab followed by adjuvant zimberelimab with or without sacituzumab govitecan in patients with resectable non-small cell lung cancer. J Clin Oncol. 2025;43:TPS8120. https:\/\/doi.org\/10.1080\/14796694.2025.2591213.","journal-title":"J Clin Oncol"},{"key":"2331_CR76","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtcvs.2025.09.017","author":"DR Jones","year":"2025","unstructured":"Jones DR, Opitz I, Harpole D, et al. TROPION-Lung12: a phase 3 study of adjuvant datopotamab deruxtecan and rilvegostomig in ctDNA-positive or high-risk pathology stage I non\u2013small cell lung cancer. J Thorac Cardiovasc Surg. 2025. https:\/\/doi.org\/10.1016\/j.jtcvs.2025.09.017.","journal-title":"J Thorac Cardiovasc Surg"},{"key":"2331_CR77","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1038\/s41571-023-00783-w","volume":"20","author":"P Tarantino","year":"2023","unstructured":"Tarantino P, Ricciuti B, Pradhan SM, Tolaney SM. Optimizing the safety of antibody\u2013drug conjugates for patients with solid tumours. Nat Rev Clin Oncol. 2023;20:558\u201376. https:\/\/doi.org\/10.1038\/s41571-023-00783-w.","journal-title":"Nat Rev Clin Oncol"},{"key":"2331_CR78","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics17020258","volume":"17","author":"P Ballest\u00edn","year":"2025","unstructured":"Ballest\u00edn P, L\u00f3pez de S\u00e1 A, D\u00edaz-Tejeiro C, et al. Understanding the toxicity profile of approved ADCs. Pharmaceutics. 2025;17:258. https:\/\/doi.org\/10.3390\/pharmaceutics17020258.","journal-title":"Pharmaceutics"},{"key":"2331_CR79","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2023.107778","volume":"26","author":"Z Fu","year":"2023","unstructured":"Fu Z, Gao C, Wu T, et al. Peripheral neuropathy associated with monomethyl auristatin E-based antibody-drug conjugates. iScience. 2023;26:107778. https:\/\/doi.org\/10.1016\/j.isci.2023.107778.","journal-title":"iScience"},{"key":"2331_CR80","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1007\/s11523-022-00912-y","volume":"17","author":"M Nishio","year":"2022","unstructured":"Nishio M, Kato T, Toyozawa R, Hida T. Management of peripheral edema in patients with MET Exon 14-mutated non-small cell lung cancer treated with small molecule MET inhibitors. Target Oncol. 2022;17:597\u2013604. https:\/\/doi.org\/10.1007\/s11523-022-00912-y.","journal-title":"Target Oncol"},{"key":"2331_CR81","doi-asserted-by":"publisher","first-page":"1732","DOI":"10.1002\/jcph.70108","volume":"65","author":"MMH Riad","year":"2025","unstructured":"Riad MMH, Brunsdon P, Menon R, Marroum P, Parikh A. Assessment of telisotuzumab vedotin drug-drug interaction potential using physiologically-based pharmacokinetic modeling and simulations. J Clin Pharmacol. 2025;65:1732\u201345. https:\/\/doi.org\/10.1002\/jcph.70108.","journal-title":"J Clin Pharmacol"},{"key":"2331_CR82","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2025.105573","volume":"10","author":"R Woodford","year":"2025","unstructured":"Woodford R, Almarzouq H, Beygozlu N, et al. Toxicity and efficacy of antibody\u2013drug conjugates in advanced solid tumors: a retrospective single-center analysis of clinical trials. ESMO Open. 2025;10:105573. https:\/\/doi.org\/10.1016\/j.esmoop.2025.105573.","journal-title":"ESMO Open"},{"key":"2331_CR83","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1016\/0002-9343(81)90577-5","volume":"70","author":"RG Crystal","year":"1981","unstructured":"Crystal RG, Gadek JE, Ferrans VJ, Fulmer JD, Line BR, Hunninghake GW. Interstitial lung disease: current concepts of pathogenesis, staging and therapy. Am J Med. 1981;70:542\u201368. https:\/\/doi.org\/10.1016\/0002-9343(81)90577-5.","journal-title":"Am J Med"},{"key":"2331_CR84","doi-asserted-by":"publisher","DOI":"10.1177\/17534666241299935","volume":"18","author":"J Shi","year":"2024","unstructured":"Shi J, Liu X, Wu L, Jiang Y, Zhang Y, Wang Y. Interstitial lung disease with antibody-drug conjugates: a real-world pharmacovigilance study based on the FAERS database during the period 2014-2023. Ther Adv Respir Dis. 2024;18:17534666241299935. https:\/\/doi.org\/10.1177\/17534666241299935.","journal-title":"Ther Adv Respir Dis"},{"key":"2331_CR85","doi-asserted-by":"publisher","first-page":"1873","DOI":"10.1001\/jamaoncol.2021.3595","volume":"7","author":"P Tarantino","year":"2021","unstructured":"Tarantino P, Modi S, Tolaney SM, et al. Interstitial lung disease induced by anti-ERBB2 antibody-drug conjugates: a review. JAMA Oncol. 2021;7:1873\u201381. https:\/\/doi.org\/10.1001\/jamaoncol.2021.3595.","journal-title":"JAMA Oncol"},{"key":"2331_CR86","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16223753","volume":"16","author":"A Desai","year":"2024","unstructured":"Desai A, Subbiah V, Roy-Chowdhuri S, Sheshadri A, Deshmukh S, Peters S. Association of antibody-drug conjugate (ADC) target expression and interstitial lung disease (ILD) in non-small-cell lung cancer (NSCLC): association or causation or neither? Cancers (Basel). 2024;16:3753. https:\/\/doi.org\/10.3390\/cancers16223753.","journal-title":"Cancers (Basel)"},{"key":"2331_CR87","doi-asserted-by":"publisher","first-page":"2081","DOI":"10.1158\/0008-5472.CAN-24-2021","volume":"85","author":"Q Wei","year":"2025","unstructured":"Wei Q, Yang T, Zhang Z, et al. Perivascular niche-resident alveolar macrophages promote interstitial pneumonitis related to Trastuzumab Deruxtecan treatment. Cancer Res. 2025;85:2081\u201399. https:\/\/doi.org\/10.1158\/0008-5472.CAN-24-2021.","journal-title":"Cancer Res"},{"key":"2331_CR88","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1200\/EDBK_280775","volume":"40","author":"S Makawita","year":"2020","unstructured":"Makawita S, Meric-Bernstam F. Antibody\u2013drug conjugates: patient and treatment selection. Am Soc Clin Oncol Educ Book. 2020;40:105\u201314. https:\/\/doi.org\/10.1200\/EDBK_280775.","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"2331_CR89","doi-asserted-by":"publisher","first-page":"S2","DOI":"10.1016\/S1556-0864(25)00196-0","volume":"20","author":"X Le","year":"2025","unstructured":"Le X, Hendriks L, Morabito A, et al. 1O: Osimertinib (osi) + datopotamab deruxtecan (Dato-DXd) in patients (pts) with EGFR-mutated (EGFRm) advanced NSCLC (aNSCLC) whose disease progressed on first-line (1L) osi: ORCHARD. J Thorac Oncol. 2025;20:S2-4. https:\/\/doi.org\/10.1016\/S1556-0864(25)00196-0.","journal-title":"J Thorac Oncol"},{"key":"2331_CR90","doi-asserted-by":"publisher","DOI":"10.1007\/s12672-024-01705-7","volume":"15","author":"J Zhu","year":"2024","unstructured":"Zhu J, Jiang R, Zhang H, et al. Advancements in research and clinical management of interstitial lung injury associated with ADC drugs administration in breast cancer. Discov Onc. 2024;15:843. https:\/\/doi.org\/10.1007\/s12672-024-01705-7.","journal-title":"Discov Onc"},{"issue":"6","key":"2331_CR91","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2023.102043","volume":"8","author":"D Wekking","year":"2023","unstructured":"Wekking D, Porcu M, Pellegrino B, et al. Multidisciplinary clinical guidelines in proactive monitoring, early diagnosis, and effective management of trastuzumab deruxtecan (T-DXd)-induced interstitial lung disease (ILD) in breast cancer patients. ESMO Open. 2023;8(6):102043. https:\/\/doi.org\/10.1016\/j.esmoop.2023.102043.","journal-title":"ESMO Open"},{"key":"2331_CR92","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2017.1395127","volume":"7","author":"RM Hoffmann","year":"2017","unstructured":"Hoffmann RM, Coumbe BGT, Josephs DH, et al. Antibody structure and engineering considerations for the design and function of antibody drug conjugates (ADCs). Oncoimmunology. 2017;7:e1395127. https:\/\/doi.org\/10.1080\/2162402X.2017.1395127.","journal-title":"Oncoimmunology"},{"key":"2331_CR93","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics17091164","volume":"17","author":"IA Alradwan","year":"2025","unstructured":"Alradwan IA, Alnefaie MK, AL Fayez N, et al. Strategic and chemical advances in antibody\u2013drug conjugates. Pharmaceutics. 2025;17:1164. https:\/\/doi.org\/10.3390\/pharmaceutics17091164.","journal-title":"Pharmaceutics"},{"key":"2331_CR94","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15030713","volume":"15","author":"TD Nguyen","year":"2023","unstructured":"Nguyen TD, Bordeau BM, Balthasar JP. Mechanisms of ADC toxicity and strategies to increase ADC tolerability. Cancers (Basel). 2023;15:713. https:\/\/doi.org\/10.3390\/cancers15030713.","journal-title":"Cancers (Basel)"},{"key":"2331_CR95","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1016\/j.ccell.2022.09.016","volume":"40","author":"R Colombo","year":"2022","unstructured":"Colombo R, Rich JR. The therapeutic window of antibody drug conjugates: a dogma in need of revision. Cancer Cell. 2022;40:1255\u201363. https:\/\/doi.org\/10.1016\/j.ccell.2022.09.016.","journal-title":"Cancer Cell"},{"key":"2331_CR96","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1002\/cpt.2278","volume":"110","author":"MZ Liao","year":"2021","unstructured":"Liao MZ, Lu D, K\u00e5gedal M, et al. Model-informed therapeutic dose optimization strategies for antibody-drug conjugates in oncology: what can we learn from US Food and Drug Administration-approved antibody-drug conjugates? Clin Pharmacol Ther. 2021;110:1216\u201330. https:\/\/doi.org\/10.1002\/cpt.2278.","journal-title":"Clin Pharmacol Ther"},{"key":"2331_CR97","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1158\/1078-0432.CCR-23-1683","volume":"30","author":"Y Guo","year":"2024","unstructured":"Guo Y, Remaily BC, Thomas J, et al. Antibody drug clearance: an underexplored marker of outcomes with checkpoint inhibitors. Clin Cancer Res. 2024;30:942\u201358. https:\/\/doi.org\/10.1158\/1078-0432.CCR-23-1683.","journal-title":"Clin Cancer Res"},{"key":"2331_CR98","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.1002\/cpt.3383","volume":"116","author":"P Zuo","year":"2024","unstructured":"Zuo P, Bonate P, Garg A, Matsangou M, Tang M. Population pharmacokinetic modeling and exposure\u2013response analysis for the antibody\u2013drug conjugate enfortumab vedotin in locally advanced or metastatic urothelial carcinoma. Clin Pharmacol Ther. 2024;116:1278\u201388. https:\/\/doi.org\/10.1002\/cpt.3383.","journal-title":"Clin Pharmacol Ther"},{"key":"2331_CR99","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1002\/cpt.70015","volume":"118","author":"AB SyBing","year":"2025","unstructured":"SyBing AB, Chen H, Wang DD. Re-evaluation of fixed dosing versus body size-based dosing approaches for large molecule therapeutics in adults. Clin Pharmacol Ther. 2025;118:1015\u201321. https:\/\/doi.org\/10.1002\/cpt.70015.","journal-title":"Clin Pharmacol Ther"},{"key":"2331_CR100","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1007\/s11523-024-01075-8","volume":"19","author":"DJAR Moes","year":"2024","unstructured":"Moes DJAR, Hendrikx JJMA, Guchelaar H-J, et al. Model-informed development of a cost-saving dosing regimen for sacituzumab govitecan. Target Oncol. 2024;19:789\u201396. https:\/\/doi.org\/10.1007\/s11523-024-01075-8.","journal-title":"Target Oncol"},{"key":"2331_CR101","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.4155\/bio.13.76","volume":"5","author":"D Lu","year":"2013","unstructured":"Lu D, Sahasranaman S, Zhang Y, Girish S. Strategies to address drug interaction potential for antibody\u2013drug conjugates in clinical development. Bioanalysis. 2013;5:1115\u201330. https:\/\/doi.org\/10.4155\/bio.13.76.","journal-title":"Bioanalysis"},{"key":"2331_CR102","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1002\/cpt.2448","volume":"112","author":"C Li","year":"2022","unstructured":"Li C, Menon R, Walles M, et al. Risk-based pharmacokinetic and drug-drug interaction characterization of antibody-drug conjugates in oncology clinical development: an International Consortium for Innovation and Quality in Pharmaceutical Development Perspective. Clin Pharmacol Ther. 2022;112:754\u201369. https:\/\/doi.org\/10.1002\/cpt.2448.","journal-title":"Clin Pharmacol Ther"},{"key":"2331_CR103","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.70060","author":"C Dello Russo","year":"2026","unstructured":"Dello Russo C, Asiimwe IG, Pushpakom S, Palmieri C, Pirmohamed M. UGT1A1 and sacituzumab govitecan toxicity: a systematic review and meta-analysis. Clin Pharmacol Ther. 2026. https:\/\/doi.org\/10.1002\/cpt.70060.","journal-title":"Clin Pharmacol Ther"},{"key":"2331_CR104","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2022.100395","volume":"7","author":"S Ren","year":"2022","unstructured":"Ren S, Wang J, Ying J, et al. Consensus for HER2 alterations testing in non-small-cell lung cancer. ESMO Open. 2022;7:100395. https:\/\/doi.org\/10.1016\/j.esmoop.2022.100395.","journal-title":"ESMO Open"},{"key":"2331_CR105","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1056\/NEJMoa2112431","volume":"386","author":"BT Li","year":"2022","unstructured":"Li BT, Smit EF, Goto Y, et al. Trastuzumab deruxtecan in HER2-mutant non\u2013small-cell lung cancer. N Engl J Med. 2022;386:241\u201351. https:\/\/doi.org\/10.1056\/NEJMoa2112431.","journal-title":"N Engl J Med"},{"key":"2331_CR106","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1016\/S1470-2045(24)00064-0","volume":"25","author":"EF Smit","year":"2024","unstructured":"Smit EF, Felip E, Uprety D, et al. Trastuzumab Deruxtecan in patients with metastatic non-small-cell lung cancer (DESTINY-Lung01): primary results of the HER2-overexpressing cohorts from a single-arm, phase 2 trial. Lancet Oncol. 2024;25:439\u201354. https:\/\/doi.org\/10.1016\/S1470-2045(24)00064-0.","journal-title":"Lancet Oncol"},{"key":"2331_CR107","doi-asserted-by":"publisher","first-page":"3492","DOI":"10.1038\/s41591-025-03885-3","volume":"31","author":"B Pistilli","year":"2025","unstructured":"Pistilli B, Mosele F, Corcos N, et al. Patritumab deruxtecan in HR+HER2\u2212 advanced breast cancer: a phase 2 trial. Nat Med. 2025;31:3492\u2013503. https:\/\/doi.org\/10.1038\/s41591-025-03885-3.","journal-title":"Nat Med"},{"key":"2331_CR108","doi-asserted-by":"publisher","first-page":"S2","DOI":"10.1016\/j.jtho.2024.09.015","volume":"19","author":"MC Garassino","year":"2024","unstructured":"Garassino MC, Sands J, Paz-Ares L, et al. PL02.11 normalized membrane ratio of TROP2 by quantitative continuous scoring is predictive of clinical outcomes in TROPION-Lung 01. J Thorac Oncol. 2024;19:S2-3. https:\/\/doi.org\/10.1016\/j.jtho.2024.09.015.","journal-title":"J Thorac Oncol"},{"key":"2331_CR109","doi-asserted-by":"publisher","DOI":"10.1200\/EDBK_431766","volume":"44","author":"L Ascione","year":"2024","unstructured":"Ascione L, Guidi L, Prakash A, et al. Unlocking the potential: biomarkers of response to antibody-drug conjugates. Am Soc Clin Oncol Educ Book. 2024;44:e431766. https:\/\/doi.org\/10.1200\/EDBK_431766.","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"2331_CR110","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1158\/2159-8290.CD-20-1638","volume":"11","author":"M Aldea","year":"2021","unstructured":"Aldea M, Andre F, Marabelle A, Dogan S, Barlesi F, Soria J-C. Overcoming resistance to tumor-targeted and immune-targeted therapies. Cancer Discov. 2021;11:874\u201399. https:\/\/doi.org\/10.1158\/2159-8290.CD-20-1638.","journal-title":"Cancer Discov"},{"key":"2331_CR111","doi-asserted-by":"publisher","first-page":"1966","DOI":"10.1158\/1078-0432.CCR-24-2771","volume":"31","author":"RO Abelman","year":"2025","unstructured":"Abelman RO, Wu B, Barnes H, et al. TOP1 mutations and cross-resistance to antibody-drug conjugates in patients with metastatic breast cancer. Clin Cancer Res. 2025;31:1966\u201374. https:\/\/doi.org\/10.1158\/1078-0432.CCR-24-2771.","journal-title":"Clin Cancer Res"},{"key":"2331_CR112","doi-asserted-by":"publisher","first-page":"2436","DOI":"10.1158\/2159-8290.CD-21-0702","volume":"11","author":"JT Coates","year":"2021","unstructured":"Coates JT, Sun S, Leshchiner I, et al. Parallel genomic alterations of antigen and payload targets mediate polyclonal acquired clinical resistance to sacituzumab govitecan in triple-negative breast cancer. Cancer Discov. 2021;11:2436\u201345. https:\/\/doi.org\/10.1158\/2159-8290.CD-21-0702.","journal-title":"Cancer Discov"},{"key":"2331_CR113","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2026.01.007","author":"MB Nilsson","year":"2026","unstructured":"Nilsson MB, Le X, Poteete A, et al. Loss of payload sensitivity and other mechanisms of resistance to T-DXd in HER2-mutant NSCLC: implications for subsequent responsiveness to HER2 TKIs. J Thorac Oncol. 2026. https:\/\/doi.org\/10.1016\/j.jtho.2026.01.007.","journal-title":"J Thorac Oncol"},{"key":"2331_CR114","doi-asserted-by":"publisher","first-page":"15030","DOI":"10.1073\/pnas.1205943109","volume":"109","author":"G Zoppoli","year":"2012","unstructured":"Zoppoli G, Regairaz M, Leo E, et al. Putative DNA\/RNA helicase Schlafen-11 (SLFN11) sensitizes cancer cells to DNA-damaging agents. Proc Natl Acad Sci USA. 2012;109:15030\u20135. https:\/\/doi.org\/10.1073\/pnas.1205943109.","journal-title":"Proc Natl Acad Sci USA"},{"key":"2331_CR115","doi-asserted-by":"publisher","DOI":"10.1038\/s41523-023-00573-8","volume":"9","author":"M Zhao","year":"2023","unstructured":"Zhao M, DiPeri TP, Raso MG, et al. Epigenetically upregulating TROP2 and SLFN11 enhances therapeutic efficacy of TROP2 antibody drug conjugate sacitizumab govitecan. NPJ Breast Cancer. 2023;9:66. https:\/\/doi.org\/10.1038\/s41523-023-00573-8.","journal-title":"NPJ Breast Cancer"},{"key":"2331_CR116","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.AM2022-4099","volume":"82","author":"SP Thyparambil","year":"2022","unstructured":"Thyparambil SP, Liao W-L, Heaton R, et al. Abstract 4099: clinical survey of Trop2 antibody drug conjugate target and payload biomarkers in multiple cancer indications using multiplex mass spectrometry. Cancer Res. 2022;82:4099. https:\/\/doi.org\/10.1158\/1538-7445.AM2022-4099.","journal-title":"Cancer Res"},{"key":"2331_CR117","doi-asserted-by":"publisher","first-page":"3747","DOI":"10.1200\/JCO.23.00013","volume":"41","author":"A Passaro","year":"2023","unstructured":"Passaro A, J\u00e4nne PA, Peters S. Antibody-drug conjugates in lung cancer: recent advances and implementing strategies. J Clin Oncol. 2023;41:3747\u201361. https:\/\/doi.org\/10.1200\/JCO.23.00013.","journal-title":"J Clin Oncol"},{"key":"2331_CR118","doi-asserted-by":"publisher","first-page":"2159","DOI":"10.1158\/0008-5472.CAN-17-3671","volume":"78","author":"S Garc\u00eda-Alonso","year":"2018","unstructured":"Garc\u00eda-Alonso S, Oca\u00f1a A, Pandiella A. Resistance to antibody-drug conjugates. Cancer Res. 2018;78:2159\u201365. https:\/\/doi.org\/10.1158\/0008-5472.CAN-17-3671.","journal-title":"Cancer Res"},{"key":"2331_CR119","doi-asserted-by":"publisher","first-page":"2089","DOI":"10.1158\/2159-8290.CD-24-0708","volume":"14","author":"R Colombo","year":"2024","unstructured":"Colombo R, Tarantino P, Rich JR, LoRusso PM, de Vries EGE. The journey of antibody\u2013drug conjugates: lessons learned from 40 years of development. Cancer Discov. 2024;14:2089\u2013108. https:\/\/doi.org\/10.1158\/2159-8290.CD-24-0708.","journal-title":"Cancer Discov"},{"key":"2331_CR120","doi-asserted-by":"publisher","first-page":"8593","DOI":"10.1200\/JCO.2024.42.16_suppl.8593","volume":"42","author":"A Lisberg","year":"2024","unstructured":"Lisberg A, Ahn M-J, Kitazono S, et al. Intracranial efficacy of datopotamab deruxtecan (Dato-DXd) in patients (pts) with previously treated advanced\/metastatic non-small cell lung cancer (a\/m NSCLC) with actionable genomic alterations (AGA): results from TROPION-Lung05. J Clin Oncol. 2024;42:8593\u20138593. https:\/\/doi.org\/10.1200\/JCO.2024.42.16_suppl.8593.","journal-title":"J Clin Oncol"},{"key":"2331_CR121","doi-asserted-by":"publisher","first-page":"S30","DOI":"10.1016\/j.jtho.2025.09.061","volume":"20","author":"E Pons-Tostivint","year":"2025","unstructured":"Pons-Tostivint E, Okamoto I, Ahn M-J, et al. OA10.01 intracranial efficacy of datopotamab deruxtecan (Dato-DXd) in patients with advanced\/metastatic NSCLC in TROPION-Lung01. J Thorac Oncol. 2025;20:S30\u20131. https:\/\/doi.org\/10.1016\/j.jtho.2025.09.061.","journal-title":"J Thorac Oncol"},{"key":"2331_CR122","doi-asserted-by":"publisher","first-page":"S762","DOI":"10.1016\/j.annonc.2023.09.2354","volume":"34","author":"BT Li","year":"2023","unstructured":"Li BT, Planchard D, Goto K, et al. 1321MO Trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2 (ERBB2)-mutant (HER2m) metastatic non-small cell lung cancer (NSCLC) with and without brain metastases (BMs): pooled analyses from DESTINY-Lung01 and DESTINY-Lung02. Ann Oncol. 2023;34:S762\u20133. https:\/\/doi.org\/10.1016\/j.annonc.2023.09.2354.","journal-title":"Ann Oncol"},{"key":"2331_CR123","doi-asserted-by":"publisher","first-page":"5202","DOI":"10.1158\/1078-0432.CCR-16-3107","volume":"23","author":"M Altan","year":"2017","unstructured":"Altan M, Pelekanou V, Schalper KA, et al. B7\u2013H3 expression in NSCLC and its association with B7\u2013H4, PD-L1 and tumor-infiltrating lymphocytes. Clin Cancer Res. 2017;23:5202\u20139. https:\/\/doi.org\/10.1158\/1078-0432.CCR-16-3107.","journal-title":"Clin Cancer Res"},{"key":"2331_CR124","doi-asserted-by":"publisher","first-page":"2653","DOI":"10.1158\/1078-0432.CCR-17-2852","volume":"24","author":"K Yonesaka","year":"2018","unstructured":"Yonesaka K, Haratani K, Takamura S, et al. B7-H3 negatively modulates CTL-mediated cancer immunity. Clin Cancer Res. 2018;24:2653\u201364. https:\/\/doi.org\/10.1158\/1078-0432.CCR-17-2852.","journal-title":"Clin Cancer Res"},{"key":"2331_CR125","doi-asserted-by":"publisher","first-page":"S1426","DOI":"10.1016\/j.annonc.2024.10.078","volume":"35","author":"Y Cheng","year":"2024","unstructured":"Cheng Y, Wu L, Parsonson A, et al. 57O A phase I\/II multicenter, first-in-human study of DB-1311\/BNT324 (a novel B7H3 ADC) in patients with advanced solid tumors. Ann Oncol. 2024;35:S1426. https:\/\/doi.org\/10.1016\/j.annonc.2024.10.078.","journal-title":"Ann Oncol"},{"key":"2331_CR126","doi-asserted-by":"publisher","first-page":"1949","DOI":"10.1038\/s41591-025-03600-2","volume":"31","author":"Y Ma","year":"2025","unstructured":"Ma Y, Yang Y, Huang Y, et al. A B7H3-targeting antibody-drug conjugate in advanced solid tumors: a phase 1\/1b trial. Nat Med. 2025;31:1949\u201357. https:\/\/doi.org\/10.1038\/s41591-025-03600-2.","journal-title":"Nat Med"},{"key":"2331_CR127","doi-asserted-by":"publisher","first-page":"2235","DOI":"10.1158\/1535-7163.MCT-20-0116","volume":"19","author":"JA Scribner","year":"2020","unstructured":"Scribner JA, Brown JG, Son T, et al. Preclinical development of MGC018, a duocarmycin-based antibody-drug conjugate targeting B7-H3 for solid cancer. Mol Cancer Ther. 2020;19:2235\u201344. https:\/\/doi.org\/10.1158\/1535-7163.MCT-20-0116.","journal-title":"Mol Cancer Ther"},{"key":"2331_CR128","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1038\/s41379-021-00979-4","volume":"35","author":"L Zong","year":"2022","unstructured":"Zong L, Gu Y, Zhou Y, et al. Expression of B7 family checkpoint proteins in cervical cancer. Mod Pathol. 2022;35:786\u201393. https:\/\/doi.org\/10.1038\/s41379-021-00979-4.","journal-title":"Mod Pathol"},{"key":"2331_CR129","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2024-009710","volume":"12","author":"Y Dong","year":"2024","unstructured":"Dong Y, Zhang Z, Luan S, et al. Novel bispecific antibody-drug conjugate targeting PD-L1 and B7\u2013H3 enhances antitumor efficacy and promotes immune-mediated antitumor responses. J Immunother Cancer. 2024;12:e009710. https:\/\/doi.org\/10.1136\/jitc-2024-009710.","journal-title":"J Immunother Cancer"},{"key":"2331_CR130","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.AM2023-2932","volume":"83","author":"D Okajima","year":"2023","unstructured":"Okajima D, Yasuda S, Suzuki T, et al. Abstract 2932: datopotamab deruxtecan (Dato-DXd) enhances antitumor response to PD-1\/PD-L1 inhibitors in TROP2-expressing tumors in mice. Cancer Res. 2023;83:2932. https:\/\/doi.org\/10.1158\/1538-7445.AM2023-2932.","journal-title":"Cancer Res"},{"key":"2331_CR131","doi-asserted-by":"publisher","DOI":"10.1097\/ot9.0000000000000099","volume":"11","author":"Z Chen","year":"2025","unstructured":"Chen Z, Lu Z, Zhang M, et al. Predictive factors of treatment efficacy and prognosis in patients with resectable non\u2013small cell lung cancer following neoadjuvant chemoimmunotherapy. Oncol Transl Med. 2025;11:221. https:\/\/doi.org\/10.1097\/ot9.0000000000000099.","journal-title":"Oncol Transl Med"},{"key":"2331_CR132","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1200\/JCO.21.01308","volume":"40","author":"DR Spigel","year":"2022","unstructured":"Spigel DR, Faivre-Finn C, Gray JE, et al. Five-year survival outcomes from the PACIFIC trial: durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer. J Clin Oncol. 2022;40:1301\u201311. https:\/\/doi.org\/10.1200\/JCO.21.01308.","journal-title":"J Clin Oncol"},{"key":"2331_CR133","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-024-01979-x","volume":"9","author":"B Wu","year":"2024","unstructured":"Wu B, Zhang B, Li B, Wu H, Jiang M. Cold and hot tumors: from molecular mechanisms to targeted therapy. Sig Transduct Target Ther. 2024;9:274. https:\/\/doi.org\/10.1038\/s41392-024-01979-x.","journal-title":"Sig Transduct Target Ther"},{"key":"2331_CR134","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-025-01080-4","author":"J Remon","year":"2025","unstructured":"Remon J, Levy A, Gille R, et al. Unresectable stage III non-small-cell lung cancer: state of the art and challenges. Nat Rev Clin Oncol. 2025. https:\/\/doi.org\/10.1038\/s41571-025-01080-4.","journal-title":"Nat Rev Clin Oncol"},{"key":"2331_CR135","doi-asserted-by":"publisher","first-page":"2281","DOI":"10.1200\/JCO.23.01909","volume":"42","author":"A Bardia","year":"2024","unstructured":"Bardia A, Krop IE, Kogawa T, et al. Datopotamab deruxtecan in advanced or metastatic HR+\/HER2- and triple-negative breast cancer: results from the phase I TROPION-PanTumor01 study. J Clin Oncol. 2024;42:2281\u201394. https:\/\/doi.org\/10.1200\/JCO.23.01909.","journal-title":"J Clin Oncol"}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-026-02331-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40265-026-02331-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-026-02331-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T06:39:20Z","timestamp":1782196760000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40265-026-02331-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,18]]},"references-count":135,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["2331"],"URL":"https:\/\/doi.org\/10.1007\/s40265-026-02331-z","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,18]]},"assertion":[{"value":"15 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"L.H. declares research funding Roche Genentech, AstraZeneca, Boehringer Ingelheim, Takeda, Merck, Pfizer, Novartis, Gilead, Summit and Amgen, all payments were made to the Institution. Speaker educationals\/webinars: AstraZeneca, Bayer, Lilly, MSD, high5oncology, Takeda, Janssen, GSK, Sanofi, Pfizer, Medtalks, Benecke, VJOncology, Medimix (all payments were paid to the Institution with the exception of Medtalks, Benecke, VJOncology, Medimix). Advisory boards: Abbvie, Amgen, Anhearth, AstraZeneca, Bayer, BMS, Boehringer Ingelheim, Daiichi, Gilead, GSK, Janssen, Lilly, Merck, MSD, Novartis, Pfizer, Pierre Fabre, Roche, Sanofi, Summit Therapeutics, Takeda, all payments were made to the Institution. Member guideline committees: Dutch guidelines on NSCLC, brain metastases and leptomeningeal metastases (payment to self), ESMO guidelines on metastatic NSCLC, non-metastatic NSCLC and SCLC (non-financial). Other (non-financial): former secretary and current chair NVALT studies foundation, secretary EORTC lung cancer group, vice-chair scientific committee Dutch Thoracic Group. Local PI of clinical trials: AstraZeneca, GSK, Novartis, Merck, Roche, Takeda, Blueprint, Mirati, Abbvie (also steering committee), Gilead, MSD, Merck, Amgen, Boehringer Ingelheim, Pfizer, Daiichi, Amgen, BMS, Revolution Medicines (all payments were made to the Institution). J.R. declares honoraria from Johnson & Johnson, MSD, Pfizer, all payments made to the Institution. Support for travel\/attending meeting from MSD and Ose Immunotherapeutics. Participation on advisory boards for Boehringer-Ingelheim, Lilly, with all payments made to the Institution. Editor in JTO, JCO OA, Lung Cancer, member ESMO guidelines Thymic Malignancies 2025\u20132026. Chair of the EORTC Lung Cancer Group. R.H. declares research funding from Amgen and Stichting Treatmeds and fees received for acting as an advisory board member for Samsung Bioepis. R.G. declares research fundings from AstraZeneca (paid to the Institution). S.P.L.S. declares grants from AstraZeneca, Haystack Oncology. Consulting fees from Pfizer, Bayer, AstraZeneca, Daiichi Sankyo, Boehringer Ingelheim and Johnson & Johnson. Honoraria from AstraZeneca, MSD, Bristol-Myers Squibb, Daiichi Sankyo, Roche, Takeda, Pfizer, Johnson & Johnson, Boehringer Ingelheim. Support for attending meetings\/travel from MSD, AstraZeneca, Daiichi Sankyo, Pfizer, BeOne, Johnson & Johnson, Boehringer Ingelheim, MSD, Bristol-Myers Squibb. Advisory boards for AstraZeneca, Daiichi Sankyo, Boehringer Ingelheim, Pfizer, Johnson & Johnson. L.Z. declares fundings from LIFEN, paid to the Institution. M.B., F.R.O., A.S. declare no competing interests","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"No datasets were generated or analyzed during the current study.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data"}},{"value":"LZ, MB, LH, JZ: conceptualization; LZ, MB, FRO, SPLS, RG, RH, AS: writing\u2014original draft; LZ, MB, FRO, SPLS, RG, RH, AS: visualization; LZ, MB, LH, JR: writing\u2014review & editing; LH, JR: supervision.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author Contributions"}}]}}